Cargando…

Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study

AIMS: To compare 12‐month clinical effectiveness of insulin glargine 300 units/mL (Gla‐300) versus first‐generation basal insulin analogues (BIAs) (insulin glargine 100 units/mL [Gla‐100] or insulin detemir [IDet]) in patients with type 2 diabetes (T2D) who were at high risk of hypoglycaemia and swi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sullivan, Sean D., Freemantle, Nick, Gupta, Rishab A., Wu, Jasmanda, Nicholls, Charlie J., Westerbacka, Jukka, Bailey, Timothy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754248/ https://www.ncbi.nlm.nih.gov/pubmed/34807513 http://dx.doi.org/10.1002/edm2.306

Ejemplares similares

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study
por: Sullivan, Sean D., et al.
Publicado: (2019)

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?
por: Mauricio, Dídac, et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)
por: Bailey, Timothy S., et al.
Publicado: (2019)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Clinical outcomes in real‐world patients with type 2 diabetes switching from first‐ to second‐generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study
por: Sullivan, Sean D., et al.
Publicado: (2018)

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
por: Zhou, Fang L., et al.
Publicado: (2019)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study
por: Bailey, Timothy S., et al.
Publicado: (2022)

Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study
por: Escalada, Javier, et al.
Publicado: (2020)

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
por: Cheng, Alice, et al.
Publicado: (2019)

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
por: Pettus, Jeremy, et al.
Publicado: (2019)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)
por: Matsuhisa, M., et al.
Publicado: (2016)

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)
por: Roussel, Ronan, et al.
Publicado: (2017)

Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
por: Müller-Wieland, Dirk, et al.
Publicado: (2023)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial
por: Haluzík, Martin, et al.
Publicado: (2020)

Comment on “a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes”
por: Freemantle, Nick, et al.
Publicado: (2019)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
por: Terauchi, Y., et al.
Publicado: (2016)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
por: Yki‐Järvinen, H., et al.
Publicado: (2015)

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial
por: Battelino, Tadej, et al.
Publicado: (2022)

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis
por: Freemantle, Nick, et al.
Publicado: (2016)

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study
por: Bailey, Timothy S., et al.
Publicado: (2019)

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
por: Lindauer, Klaus, et al.
Publicado: (2019)

A post‐hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in individuals with type 2 diabetes on a basal‐only insulin regimen
por: Bolli, Geremia B., et al.
Publicado: (2018)

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
por: Gourdy, Pierre, et al.
Publicado: (2019)

Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2020)

Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures
por: Lingvay, Ildiko, et al.
Publicado: (2017)

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials
por: Danne, Thomas, et al.
Publicado: (2020)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
por: Home, Philip D., et al.
Publicado: (2017)

Improving Type 2 Diabetes Management in General Practice Using a Second-Generation Basal Insulin Analogue Insulin Glargine 300 U/mL: A Practical Guide
por: Deed, Gary, et al.
Publicado: (2019)

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
por: Bolli, Geremia B., et al.
Publicado: (2020)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12‐month comparison by concomitant sulphonylurea and/or glinide use
por: Terauchi, Yasuo, et al.
Publicado: (2018)

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
por: Ritzel, R, et al.
Publicado: (2015)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme
por: Blonde, Lawrence, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fe2n79dcj14plhhanml6soq5qn